Tirzepatide (Mounjaro®/Zepbound®): Dual GLP-1/GIP — Complete Analysis
Educational Content Only
The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.
⚠️ The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.
Scientific guide to Tirzepatide (Mounjaro®, Zepbound®): dual GLP-1+GIP mechanism, data from SURMOUNT (obesity) and SURPASS (T2D) trials, −22.5% body weight efficacy and FDA approval 2023. Includes free syringe dose calculator.
Mechanism of Action
Tirzepatide is an innovative molecule classified as a "twincretin" — a dual GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 receptor agonist. It consists of a 39-amino acid peptide based on the native GIP sequence, with modifications allowing GLP-1R binding, coupled to a C20 fatty acid chain for half-life extension.
1. Dual GIP-R + GLP-1R agonism
Tirzepatide simultaneously activates GIP-R (with potency ≈ native GIP) and GLP-1R (with potency ≈ 5× lower than semaglutide, but sufficient for clinical effect). Dual activation produces complementary effects on insulin secretion, adipogenesis and energy balance.
2. GIP-R role in adipogenesis and insulin resistance
GIP-R is expressed in adipocytes, where it regulates lipogenesis and lipolysis. In obesity states, endogenous GIP may contribute to fat accumulation. Paradoxically, intense pharmacological GIP-R agonism with Tirzepatide appears to produce distinct effects (receptor desensitization or metabolically context-dependent effects), contributing to body fat reduction in clinical trials.
3. Weight loss superiority vs. pure GLP-1 RAs
SURMOUNT and SURPASS trials demonstrate superior weight loss to semaglutide in direct comparisons. The proposed mechanism is that GIP agonism potentiates GLP-1R signaling via mechanisms still under investigation, additionally contributing independently to energy balance via adipose tissue.
- •FDA approved: T2DM as Mounjaro (2022) and obesity as Zepbound (2023)
- •Half-life: ~5 days → weekly dosing
- •Documented weight loss: up to ~22.5% at 72 weeks (SURMOUNT-1, 15 mg dose)
Applications Described in Literature
Type 2 diabetes mellitus — approved indication (Mounjaro)
High evidenceThe SURPASS program (5 Phase 3 trials) demonstrated HbA1c reduction of 1.87–2.59% and superiority to semaglutide 1 mg in SURPASS-2. FDA approved in May 2022 as Mounjaro for T2DM.
Obesity — approved indication (Zepbound)
High evidenceSURMOUNT-1 (N=2,539, without DM): Tirzepatide 5/10/15 mg vs. placebo over 72 weeks. Mean weight loss: 15%, 19.5% and 20.9% vs. 3.1% placebo. The 15 mg dose achieved ≥20% loss in 56% of participants.
Direct comparison with Semaglutide (SURPASS-2)
High evidenceSURPASS-2 randomized 1,879 patients with T2DM to Tirzepatide (5/10/15 mg) vs. semaglutide 1 mg/week. All Tirzepatide doses showed superiority in HbA1c and body weight reduction. Tirzepatide 15 mg: −2.46% HbA1c and −11.2 kg vs. −1.86% and −5.7 kg with semaglutide 1 mg.
Relevant Studies
2 curated studies · 2021–2022
Peer-reviewed evidence with PMID verifiable on PubMed
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff AM, Aronne LJ, Ahmad NN, et al. · New England Journal of Medicine
SURMOUNT-1: N=2,539, 72 weeks. Tirzepatide 15 mg: 20.9% body weight loss. 56% of participants achieved ≥20% loss. Pivotal study for Zepbound approval.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
Frías JP, Davies MJ, Rosenstock J, et al. · New England Journal of Medicine
First head-to-head comparison: Tirzepatide vs. semaglutide 1 mg in T2DM. Tirzepatide at all doses demonstrated superiority in HbA1c and weight.
Latest literature review: 2026-04 · PubMed
FAQ
Is Tirzepatide more effective than Semaglutide for weight loss?
In indirect comparison between separate studies, Tirzepatide (SURMOUNT-1) showed mean weight loss of 22.5% vs 14.9% with Semaglutide (STEP 1) at maximum doses. SURPASS-2 directly compared both and confirmed Tirzepatide superiority.